TrialArthritis & rheumatology (Hoboken, N.J.)2021

Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.

Kerry A Casey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.